Evolent Health (NYSE:EVH) Reports Q4 CY2025 In Line With Expectations

Evolent Health (NYSE:EVH) Reports Q4 CY2025 In Line With Expectations

Anthony Lee

Wed, February 25, 2026 at 6:46 AM GMT+9 5 min read

In this article:

EVH

-7.58%

Healthcare solutions company Evolent Health (NYSE:EVH) met Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 27.5% year on year to $468.7 million. The company’s full-year revenue guidance of $2.5 billion at the midpoint came in 4.9% above analysts’ estimates. Its non-GAAP profit of $0.08 per share was 62.7% above analysts’ consensus estimates.

Is now the time to buy Evolent Health? Find out in our full research report.

Evolent Health (EVH) Q4 CY2025 Highlights:

**Revenue:** $468.7 million vs analyst estimates of $469 million (27.5% year-on-year decline, in line)

**Adjusted EPS:** $0.08 vs analyst estimates of $0.05 (62.7% beat)

**Adjusted EBITDA:** $37.79 million vs analyst estimates of $35.71 million (8.1% margin, 5.8% beat)

**EBITDA guidance for the upcoming financial year 2026** is $125 million at the midpoint, below analyst estimates of $151.6 million

**Operating Margin:** -87.1%, down from -2.9% in the same quarter last year

**Free Cash Flow** was $41.04 million, up from -$32.38 million in the same quarter last year

**Sales Volumes** rose 6% year on year (4.2% in the same quarter last year)

**Market Capitalization:** $309.1 million

Company Overview

Founded in 2011 to transform how healthcare is delivered to patients with complex needs, Evolent Health (NYSE:EVH) provides specialty care management services and technology solutions that help health plans and providers deliver better care for patients with complex conditions.

Revenue Growth

Examining a company’s long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Luckily, Evolent Health’s sales grew at a solid 15.2% compounded annual growth rate over the last five years. Its growth beat the average healthcare company and shows its offerings resonate with customers.

Evolent Health Quarterly Revenue

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Evolent Health’s recent performance marks a sharp pivot from its five-year trend as its revenue has shown annualized declines of 2.3% over the last two years.

Evolent Health Year-On-Year Revenue Growth

We can better understand the company’s revenue dynamics by analyzing its number of average lives on platform, which reached 79.68 million in the latest quarter. Over the last two years, Evolent Health’s average lives on platform averaged 5.5% year-on-year growth. Because this number is better than its revenue growth, we can see the company’s average selling price decreased.

Evolent Health Average Lives on Platform

This quarter, Evolent Health reported a rather uninspiring 27.5% year-on-year revenue decline to $468.7 million of revenue, in line with Wall Street’s estimates.

Story continues  

Looking ahead, sell-side analysts expect revenue to grow 27.8% over the next 12 months, an improvement versus the last two years. This projection is eye-popping and implies its newer products and services will fuel better top-line performance.

While Wall Street chases Nvidia at all-time highs, an under-the-radar semiconductor supplier is dominating a critical AI component these giants can’t build without. Click here to access our free report one of our favorites growth stories.

Operating Margin

Operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses – everything from the cost of goods sold to advertising and wages. It’s also useful for comparing profitability across companies with different levels of debt and tax rates because it excludes interest and taxes.

Evolent Health’s high expenses have contributed to an average operating margin of negative 6.5% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It’s hard to trust that the business can endure a full cycle.

Looking at the trend in its profitability, Evolent Health’s operating margin decreased by 17.2 percentage points over the last five years. This performance was caused by more recent speed bumps as the company’s margin fell by 18.2 percentage points on a two-year basis. We’re disappointed in these results because it shows its expenses were rising and it couldn’t pass those costs onto its customers.

Evolent Health Trailing 12-Month Operating Margin (GAAP)

This quarter, Evolent Health generated a negative 87.1% operating margin.

Earnings Per Share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions.

Evolent Health’s full-year EPS flipped from negative to positive over the last five years. This is encouraging and shows it’s at a critical moment in its life.

Evolent Health Trailing 12-Month EPS (Non-GAAP)

In Q4, Evolent Health reported adjusted EPS of $0.08, up from negative $0.02 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Evolent Health’s full-year EPS of $0.09 to grow 173%.

Key Takeaways from Evolent Health’s Q4 Results

It was good to see Evolent Health beat analysts’ EPS expectations this quarter. We were also glad its full-year revenue guidance trumped Wall Street’s estimates. On the other hand, its full-year EBITDA guidance missed. Overall, we think this was a mixed quarter. The stock remained flat at $2.53 immediately after reporting.

So do we think Evolent Health is an attractive buy at the current price? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it’s free.

Terms and Privacy Policy

Privacy Dashboard

More Info